Egyptian Association of Vascular Biology and Atherosclerosis (EAVA) consensus on the usage of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors

Reda, Ashraf; Elserafy, Ahmed Shawky; Farag, Elsayed; Mostafa, Tamer; Farag, Nabil; Elbahry, Atef; Sanad, Osama; Bendary, Ahmed; Elkersh, Ahmed; Selim, Mohammed; Beshay, Morad; Khamis, Hazem

doi:10.1186/s43044-020-00058-0

Cited by 5 publications

(3 citation statements)

References 40 publications

(46 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…PCSK9 inhibitor, added to ezetimibe, may also be considered to reach the LDL target level [1,10,11]. We endorse the recommendations of the Egyptian Association of Vascular Biology and Atherosclerosis (EAVA) on the usage of PCSK9 inhibitors in addition to statins ± ezetimibe in patients with ASCVD, by definition at very high risk; patients with ASCVD at very high risk who do not tolerate appropriate doses of at least three statins; and familial hypercholesterolemia patients with clinically diagnosed ASCVD, at very high CV risk [12].…”

Section: What Is the Therapeutic Regimen?mentioning

confidence: 92%

Egyptian practical guidance in lipid management 2020

et al. 2021

Self Cite

View full text Add to dashboard Cite

Background Numerous epidemiological investigations and randomized clinical studies have determined that dyslipidemia is a major contributor to atherosclerotic cardiovascular disease (ASCVD). Consequently, the management of serum cholesterol and low-density lipoprotein levels has become a central objective in the effort to prevent cardiovascular events. Main body Many guidelines were issued by different organizations and societies to define patient risk and establish important recommendations for management strategies. Newer cholesterol-lowering agents (non-statin drugs) are described, and their use is directed primarily to secondary prevention in patients at very high risk of new ASCVD. Conclusion The present guidance summarizes the current methods for risk estimation and outlines the most recent data on lipid management in a simple user-friendly format, to improve physician awareness and help implement guidelines in the daily practice.

show abstract

Section: What Is the Therapeutic Regimen?mentioning

confidence: 92%

Egyptian practical guidance in lipid management 2020

et al. 2021

Self Cite

View full text Add to dashboard Cite

show abstract

“…Estimates for prevalence of hyperlipidemia according to World Health Organization in 2008 were 30.3% for the Southeast Asia, 36.7% for the Western Pacific, 53.7% for Europe and 47.7% for the Americas (Lin et al, 2018). Compared to other countries, Egypt has recorded a high prevalence of hyperlipidemia which reached up to 71% in female participants as reported from the data collected from the project of CardioRisk that was conducted recently throughout Egypt (Reda et al, 2020). Dietary factors are the most important risk factors for hyperlipidemia and hence cardiovascular and hepatic diseases.…”

Section: Introductionmentioning

confidence: 93%

Relationship Between High Consumption of Fresh Whole Milk or Yogurt and the Risk for Both Cardiovascular Diseases and Liver Disorders in Hyperlipidemic Wistar Rats

Mahmoud

Badawy

Mohammed

2021

J microb biotech food sci

View full text Add to dashboard Cite

A rapid increase in the prevalence of hyperlipidemia was recorded recently. The link between consumption of milk or dairy products with higher risk for cardiovascular diseases (CVD) and liver disorders particularly in those individuals with hyperlipidemia is still controversial. The present study was conducted to show the relationship between increased consumption of milk and yogurt either of cow or buffalo origin and the risk for cardiovascular diseases and liver disorders in hyperlipidemic rats. An animal experiment was conducted on six groups each comprising six rats after a period of eight weeks for induction of hyperlipidemia. Then, four groups of the hyperlipidemic rats were fed on 30% of milk (either buffalo or cow) or yogurt (either buffalo or cow) for another 8 weeks in addition to control negative and control positive groups. Results for the hyperlipidemic groups which received milk or yogurt revealed a reduction in most of serum lipid parameters, atherogenic index, malondialdehyde while increased HDL-C concentration. Also, a reduced activity of liver enzymes ALT, AST and LDH-5 and the cardiac enzyme CPK was noticed for the same groups in comparison with the group of control positive. Histopathological examination for liver and aorta confirmed the aforementioned biochemical changes. Thus, it can be concluded that increased milk or yogurt consumption did not increase the risk for cardiovascular diseases or liver disorders in hyperlipidemic rats. On the contrary, it improves the enzyme activity of both liver and heart and the atherogenic index, also it improves the disturbed serum lipid parameters of hyperlipidemic rats.

show abstract

“…These lower control rates could be attributed to a lack of implementation of evidence-based guidelines, clinical inertia, and patients’ non-compliance to the prescribed treatment [ 49 ]. Similarly, less affordability to costly medications and “ceiling effect” on LDL-C lowering by statin therapy could be the reason for poor control rates in the lipid levels [ 50 , 51 ].…”

Section: Main Textmentioning

confidence: 99%

A semi-systematic review on hypertension and dyslipidemia care in Egypt—highlighting evidence gaps and recommendations for better patient outcomes

Reda

Ragy

Saeed³

et al. 2021

J. Egypt. Public. Health. Assoc.

Self Cite

View full text Add to dashboard Cite

Background Both hypertension and dyslipidemia are considered as major modifiable risk factors of cardiovascular diseases (CVDs), and their prevalence in Egypt has increased in recent years. Evidence-based systematic evaluation of data on hypertension and dyslipidemia is critical for effective patient-centric management to reduce the overall risk of CVDs in Egypt. This semi-systematic review aimed to quantify and identify data gaps in the prevalence and distribution of patient journey touchpoints including awareness, screening, diagnosis, treatment, adherence, and control of hypertension and dyslipidemia to provide the basis for research prioritization, practice guidance, and health care reforms in Egypt. Main body Structured search was conducted on MEDLINE and Embase to identify articles published in English between January 2010 and December 2019 that reported key patient journey touchpoints in hypertension and dyslipidemia management. Unstructured search was conducted on public or government websites with no date restriction. Data from all sources were extracted and presented descriptively. In total, 22 studies published between 1995 and 2020 on hypertension and dyslipidemia were included in the final analyses. The prevalence of hypertension in Egypt ranged from 12.1 to 59%. Studies reported awareness (37.5% and 43.9%), diagnosis (42% and 64.7%), treatment (24% and 54.1%), and adherence to antihypertensive medication (51.9%) to be low. Furthermore, the percentage of patients who had their blood pressure controlled ranged from 8 to 53.2%. The prevalence of dyslipidemia varied in the general population (range 19.2–36.8%) but was higher in patients with acute coronary syndrome (ACS) (50.9% and 52.5%) and coronary artery disease (58.7%). A national report indicated that 8.6% of the general population was screened for dyslipidemia; however, no data was available on the diagnosis and treatment rates. Among ACS patients, 73.9% were treated for dyslipidemia. Data indicated low levels of medication adherence (59%) among dyslipidemia patients, with overall low control rates ranging from 5.1 to 34.4% depending on CVD risk in populations including ACS patients. Conclusion Data on patient journey touchpoints of hypertension and dyslipidemia are limited in Egypt, indicating the need for more systematic and high-quality evidence-based studies covering different aspects of patient-centric management for better management of CVD and its risk factors.

show abstract

Egyptian Association of Vascular Biology and Atherosclerosis (EAVA) consensus on the usage of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors

Cited by 5 publications

References 40 publications

Egyptian practical guidance in lipid management 2020

Egyptian practical guidance in lipid management 2020

Relationship Between High Consumption of Fresh Whole Milk or Yogurt and the Risk for Both Cardiovascular Diseases and Liver Disorders in Hyperlipidemic Wistar Rats

A semi-systematic review on hypertension and dyslipidemia care in Egypt—highlighting evidence gaps and recommendations for better patient outcomes

Contact Info

Product

Resources

About